| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -12,769 | 3,252 | -25,295 | -64,811 |
| Unrealized gain (loss) on investments | 43 | -39 | -94 | 542 |
| Comprehensive loss | -12,726 | 3,213 | -25,389 | -64,269 |
| Net loss per common share, basic (usd per share) | -0.04 | 0.01 | -0.07 | -0.18 |
| Net loss per common share, diluted (usd per share) | -0.04 | 0.01 | -0.07 | -0.18 |
| Weighted average common shares outstanding, basic (in shares) | 363,399,000 | 363,294,000 | 362,073,000 | 361,492,000 |
| Weighted average common shares outstanding, diluted (in shares) | 363,399,000 | 363,570,000 | 362,073,000 | 361,492,000 |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)